Last reviewed · How we verify
thrombogram
thrombogram is a Biologic drug developed by Institut Cancerologie de l'Ouest. It is currently in Phase 1 development.
The thrombogram is a type of coagulation test used to assess coagulation and thrombotic risk by measuring the potential of plasma to generate thrombin over time. It is based on the activation of coagulation via addition of phospholipids, tissue factor, and calcium, and is often used in studies of conditions such as thrombosis, bleeding, and hemostatic disorders.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | thrombogram |
|---|---|
| Sponsor | Institut Cancerologie de l'Ouest |
| Modality | Biologic |
| Therapeutic area | Cardiovascular |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Thrombin Generation and Prediction of Thromboembolic Events in Oncology Patients at Risk (NA)
- Coagulopathy in Childhood Acute Lymphoblastic Leukaemia
- Thrombin Generation Values and Percutaneous Coronary Intervention Results.
- The Correlation Between The New Sepsis Scores - SOFA, Quick SOFA and Calibrated Automated Thrombogram Values
- The Thrombotic Potential of Heart Chambers in the Presence or Absence of Atrial Fibrillation.
- Evaluation of a Standardized Protocol for Thrombin Generation Assay
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- thrombogram CI brief — competitive landscape report
- thrombogram updates RSS · CI watch RSS
- Institut Cancerologie de l'Ouest portfolio CI
Frequently asked questions about thrombogram
What is thrombogram?
Who makes thrombogram?
What development phase is thrombogram in?
Related
- Manufacturer: Institut Cancerologie de l'Ouest — full pipeline
- Therapeutic area: All drugs in Cardiovascular
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing